Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-39306579

RESUMEN

BACKGROUND AND OBJECTIVES: Stem cell mobilization is a well-known procedure to harvest hematopoietic stem cells for autologous stem cell transplantation in certain hematologic diseases. Numerous studies have been conducted to identify risk factors for poor mobilization but there are no studies that identify good mobilizers. In our hospital, we decided to explore good mobilizers, defining them as those with ≥40 CD34+ cells/µL on Day +4 in order to start early apheresis. MATERIAL AND METHODS: A descriptive retrospective study was performed at Hospital Universitari Son Espases. A total of 198 patients mobilized with doses of around 10 µg/kg of granulocyte colony-stimulating factor (G-CSF) every 12 h were analyzed for autologous collection between January 2015 and September 2022. Fifty patients who had ≥40 CD34+ cells/µL on Day +4 started early apheresis; the rest continued mobilization as planned. Success was defined as obtaining over 2.5 × 106 CD34+ cells/kg in a single apheresis. RESULTS: The necessary number of CD34+ cells/kg to perform an autologous stem cell transplantation was reached in a single apheresis session in 62 % of patients with ≥40 CD34+ cells/µL in peripheral blood. A cutoff of 102 CD34+ cells/µL on Day +4 was shown to have the best success rate (94 %). In an analysis of success, age, previously failed mobilization and having one or more adverse factors for bad mobilization were statistically significant. CONCLUSION: Patients considered as good mobilizers were matched with our factors of poor mobilization, revealing that most patients (79 %) had none or only one risk factor for poor mobilization. Apheresis on Day +4 in good mobilizers was shown to be an effective alternative to reduce mobilization duration and decrease the amount of granulocyte-colony stimulating factor administered.

2.
Clin Transl Oncol ; 20(4): 542-549, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28905209

RESUMEN

PURPOSE: The fusion gene BCR-ABL has an important role to the progression of chronic myeloid leukemia (CML) and several signaling pathways have been characterized as responsible for the terminal blastic phase (BP). However, the initial phase, the chronic phase (CP), is long lasting and there is much yet to be understood about the critical role of BCR-ABL in this phase. This study aims to evaluate transcriptional deregulation in CD34+ hematopoietic cells (CD34+ cells) from patients with untreated newly diagnosed CML compared with CD34+HC from healthy controls. METHODS: Gene expression profiling in CML-CD34 cells and CD34 cells from healthy controls were used for this purpose with emphasis on five main pathways important for enhanced proliferation/survival, enhanced self-renewal and block of myeloid differentiation. RESULTS: We found 835 genes with changed expression levels (fold change ≥ ±2) in CML-CD34 cells compared with CD34 cells. These include genes belonging to PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways. Four of these pathways converge to MYC activation. We also identified five transcripts upregulated in CD34-CML patients named OSBPL9, MEK2, p90RSK, TCF4 and FZD7 that can be potential biomarkers in CD34-CML-CP. CONCLUSION: We show several mRNAs up- or downregulated in CD34-CML during the chronic phase.


Asunto(s)
Biomarcadores de Tumor/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Transducción de Señal/genética , Transcriptoma , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antígenos CD34 , Quinasas MAP Reguladas por Señal Extracelular/genética , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Femenino , Proteínas Hedgehog/genética , Proteínas Hedgehog/metabolismo , Células Madre Hematopoyéticas/patología , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/metabolismo , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Masculino , Persona de Mediana Edad , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/genética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptores Notch/genética , Receptores Notch/metabolismo , Vía de Señalización Wnt/genética , Adulto Joven
3.
Acta méd. costarric ; 56(2): 65-70, abr.-jun. 2014. tab
Artículo en Español | LILACS | ID: lil-709110

RESUMEN

Antecedentes: evaluar el rendimiento y calidad de las recolecciones de células madre en sangre periférica realizadas en el Hospital México entre junio del 2010 hasta junio del 2012, dado que existe una dosis mínima de células CD34+(células progenitoras hematopoyéticas) que definen la posibilidad de éxito del injerto en el trasplante de células madre. Métodos: estudio retrospectivo utilizando los registros de los pacientes y los procedimientos de recolecciones de células madre por aféresis efectuados en el servicio de hematología Hospital México. Para evaluar el rendimiento y calidad de las recolecciones y el efecto de estas en los tiempos de recuperación de los parámetros hematológicos de los pacientes trasplantados entre junio del 2010 y junio del 2012...


Asunto(s)
Humanos , Eliminación de Componentes Sanguíneos , Recolección de Muestras de Sangre , Células Madre Hematopoyéticas , Control de Calidad , Células Madre
4.
Rev. cuba. hematol. inmunol. hemoter ; 27(4): 429-434, oct.-dic. 2011.
Artículo en Español | CUMED | ID: cum-54127

RESUMEN

En 35 pacientes que debían recibir terapia celular regenerativa se evaluó el efecto estimulante de 2 factores estimuladores de colonias de granulocitos de producción cubana: Hebervital y Leukocim, para la movilización de células madre hematopoyéticas hacia la sangre periférica. Los pacientes se seleccionaron de forma aleatoria en 2 grupos de tratamiento y se les suministró por vía subcutánea una dosis total de 40 mg/kg distribuidos en 4 subdosis de 10 mg/kg administrados cada 12 horas. Se realizó el conteo de las células mononucleares y células CD34+ en sangre periférica mediante citometría de flujo, antes y después de la estimulación. No se encontraron diferencias estadísticamente significativas en los conteos de las células CD34+ obtenidas posestimulación con el Hebervital y el Leukocim(AU)


In 35 patients who should have received regenerative cell therapy, it was evaluated the effect of 2 domestic production granulocyte colony stimulating factors: Leukocim and Hebervital for the mobilization of hematopoietic stem cells into peripheral blood. Patients were randomly selected into 2 treatment groups and were given a total dose of 40 mg/kg in 4 sub-doses of 10 mg/kg subcutaneously administered every 12 hours. Count was performed for mononuclear cells and CD34+ cells in peripheral blood by flow cytometry before and after stimulation. There were no statistically significant differences in the counts of CD34+ cells obtained after stimulation with Hebervital and Leukocim(AU)


Asunto(s)
Humanos , Masculino , Femenino , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/métodos , Medicina Regenerativa/métodos
5.
Rev. cuba. hematol. inmunol. hemoter ; 27(4): 429-434, oct.-dic. 2011.
Artículo en Español | LILACS | ID: lil-615372

RESUMEN

En 35 pacientes que debían recibir terapia celular regenerativa se evaluó el efecto estimulante de 2 factores estimuladores de colonias de granulocitos de producción cubana: Hebervital y Leukocim, para la movilización de células madre hematopoyéticas hacia la sangre periférica. Los pacientes se seleccionaron de forma aleatoria en 2 grupos de tratamiento y se les suministró por vía subcutánea una dosis total de 40 mg/kg distribuidos en 4 subdosis de 10 mg/kg administrados cada 12 horas. Se realizó el conteo de las células mononucleares y células CD34+ en sangre periférica mediante citometría de flujo, antes y después de la estimulación. No se encontraron diferencias estadísticamente significativas en los conteos de las células CD34+ obtenidas posestimulación con el Hebervital y el Leukocim


In 35 patients who should have received regenerative cell therapy, it was evaluated the effect of 2 domestic production granulocyte colony stimulating factors: Leukocim and Hebervital for the mobilization of hematopoietic stem cells into peripheral blood. Patients were randomly selected into 2 treatment groups and were given a total dose of 40 mg/kg in 4 sub-doses of 10 mg/kg subcutaneously administered every 12 hours. Count was performed for mononuclear cells and CD34+ cells in peripheral blood by flow cytometry before and after stimulation. There were no statistically significant differences in the counts of CD34+ cells obtained after stimulation with Hebervital and Leukocim


Asunto(s)
Humanos , Masculino , Femenino , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/métodos , Medicina Regenerativa/métodos
6.
Rev. bras. hematol. hemoter ; Rev. bras. hematol. hemoter;30(supl.2): 18-23, jun. 2008.
Artículo en Inglés | LILACS | ID: lil-496439

RESUMEN

Hemopoietic progenitor cells give rise to all cellular elements of the blood and are of importance as a potential source of cells used for correction of various pathological conditions. The main objective of this study was to identify and quantitative hemopoietic progenitor cell in antenatal fetal blood, in cord blood at the time of delivery and in adult blood, using monoclonal antibodies to surface markers and flow cytometry. CD34+ cells, most of them probably representing progenitor cells, were detected in prenatal fetal blood as early as the 17th week of gestation. The proportion of these cells showed a tendency to decrease as the pregnancy progressed. Within the population of CD34+ cells, a relatively low proportion (less than 1 percent) were negative for the surface marker CD33 or HLA-Dr, indicating a population of primitive stem cells, i.e., progenitor cells no committed to a specific lineage. On the contrary, another group coexpressed CD33 or HLA-Dr, being more mature progenitor cells already committed to differentiate along a specific lineage. The percentage of CD34+ obtained in blood of adult patients after mobilization with chemotherapeutic agents and growth factors showed an average value of 2.7± 3.1 percent. The percentage of CD34+ in the apheresis products of various patients varied from 0.58 to 1.48. In some cases the cells were reinfused in the patient with good results. Our findings are in agreement with previous studies suggesting that CD34+ stem cells is a heterogeneous population, with each subset having variable degree o commitment to differentiate toward a specific cell lineage.


As células progenitoras hematopoéticas são as responsáveis pela produção de todos os elementos do sangue e são as potenciais fontes de células usadas para o tratamento de várias condições patológicas. O principal objetivo deste trabalho foi identificar e quantificar as células progenitoras hematopoiéticas no sangue fetal do período pré-natal, no sangue de cordão umbilical no momento do parto e no sangue do adulto, usando anticorpos monoclonais para marcadores de superfície e citometria de fluxo. As células CD34+ na maioria das vezes representam células progenitoras e foram detectadas no sangue fetal pré-natal tão precoce como na 17ª semana de gestação. A proporção destas células mostrou a tendência de diminuir durante a progressão da gestação. Dentro da população de células CD34+, uma proporção relativamente pequena (menos de 1 por cento) foi negativa para os marcadores de superfície CD33 ou HLA-Dr, indicando uma população de células primitivas, isto é, células progenitoras não comissionadas com uma linhagem específica. Ao contrário, outro grupo co-expressa CD33 ou HLA-Dr, sendo progenitores celulares mais maduros já comprometidos com linhagens específicas. A porcentagem de CD34+ obtida no sangue de adultos após mobilização com agentes quimioterápicos e fator de crescimento mostrou uma média de 2.7+/-3.1 por cento. 0 por cento de CD34+ no produto aferético de vários pacientes variou de 0.58 a 1.48. Em alguns casos as células foram infundidas nos pacientes com bons resultados. Nossos achados estão de acordo com estudos prévios sugerindo que células CD34+ sejam uma população heterogênea com cada subgrupo apresentando graus de comprometimento com diferentes linhagens específicas.


Asunto(s)
Humanos , Eliminación de Componentes Sanguíneos , Sangre Fetal , Citometría de Flujo , Movilización de Célula Madre Hematopoyética , Células Madre Hematopoyéticas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA